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Abstract
Interferon-induced transmembrane (IFITM) proteins are a family of viral restriction factors that inhibit the entry processes of
several pathogenic viruses, including influenza A virus (IAV), in vitro. Here we report that IAV-infected knockout mice lacking
the Ifitm locus on chromosome 7 exhibited accelerated disease progression, greater mortality, and higher pulmonary and
systemic viral burdens as compared to wild type controls. We further observed that the phenotype of Ifitm3-specific
knockout mice was indistinguishable from that of mice lacking the entire Ifitm locus. Ifitm3 was expressed by IAV target cells
including alveolar type II pneumocytes and tracheal/bronchial respiratory epithelial cells. Robust Ifitm3 expression was also
observed in several tissues in the absence of infection. Among murine Ifitm promoters, only that of Ifitm3 could be induced
by type I and II interferons. Ifitm3 could also be upregulated by the gp130 cytokines IL-6 and oncostatin M on cells
expressing appropriate receptors, suggesting that multiple cytokine signals could contribute to Ifitm3 expression in a cell or
tissue-specific manner. Collectively, these findings establish a central role for Ifitm3 in limiting acute influenza in vivo, and
provide further insight into Ifitm3 expression and regulation.
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Introduction
The interferon-induced transmembrane (IFITM) proteins are a
family of small transmembrane proteins that mediate some of the
antiviral activities of type I and II interferons [1,2,3]. IFITM-
mediated restriction is specific to particular virus families.
Influenza A viruses (IAV), Ebola virus (EBOV), Marburg virus
(MARV), SARS coronavirus (SARS-CoV), dengue virus, and
West Nile virus are all efficiently restricted by one or more IFITM
family proteins. Conversely, IFITM proteins do not restrict
murine leukemia virus (MLV), a range of alphaviruses, and
arenaviruses including Machupo virus (MACV), Lassa virus
(LASV), and lymphocytic choriomeningitis virus (LCMV)
[2,4,5]. Vesicular stomatitis virus is inefficiently restricted [6,7].
Two groups have reported cell line-specific restriction of HIV-1
[1,8], but these reports differ as to which cell lines show efficient
restriction. Restriction activity against non-enveloped viruses has
not been reported to date.
The mechanism of action of IFITM-mediated restriction has
not yet been determined. Multiple lines of evidence indicate that
restriction occurs after virion endocytosis but during or prior to
membrane fusion. IFITM proteins prevent infection by retrovi-
ruses pseudotyped with entry proteins of IFITM-restricted viruses,
but not those pseudotyped with entry proteins of unrestricted
viruses [4]. Entry assays using virions containing b-lactamase-Vpr
(BlaM-Vpr) fusion proteins likewise reveal that IFITM proteins
prevent transfer of BlaM-Vpr to the cytosol of target cells [8].
Previously, we showed by fluorescent microscopy that labeled IAV
virions are internalized normally and traffic to acidified endocytic
compartments despite IFITM expression [4], a conclusion
confirmed and extended by Feely et al. using a rigorous set of
imaging studies. They further demonstrated by fluorescent in situ
hybridization that IFITM proteins cause sequestration and
accumulation of IAV genetic material in late endocytic/lysosomal
compartments [9].
IFITM proteins also localize to late endosomes/lysosomes as
demonstrated by co-localization with LAMP1, LAMP2, and
CD63 [4]. Moreover, IFITM protein over-expression – and in
some cell lines, interferon treatment – results in enlargement of
these organelles [9]. Finally, a recent report showed that
endosomes in interferon-treated Ifitm knockout cells are ineffi-
ciently acidified and suggested that a physical association between
Ifitm3 and a subunit of the vacuolar ATPase complex mediates
this effect [10]. It appears, therefore, that IFITM proteins alter the
properties of late endosomes and lysosomes, and render these
organelles inhospitable to viral fusion. Such a model is supported
by the pattern of IFITM-mediated restriction; excepting HIV-1,
restricted viruses generally fuse late in the endocytic pathway
whereas unrestricted viruses fuse at the plasma membrane or in
early endocytic compartments. Further evidence that restriction
depends on the site of viral fusion comes from investigation of
SARS-CoV. SARS-CoV requires lysosomal cathepsins to activate
its entry protein and fuse with the lysosomal membrane [11].
Treating receptor-bound virions with trypsin, however, removes
this cathepsin dependency, induces fusion at the plasma
membrane, and bypasses IFITM-mediated entry restriction [4].
Most vertebrates have two or more IFITM genes [12]. The
human IFITM family is composed of four functional genes,
PLOS Pathogens | www.plospathogens.org 1 September 2012 | Volume 8 | Issue 9 | e1002909IFITM1, 2, 3, and 5. Murine Ifitm1, 2, 3, and 5, located on
chromosome 7, are clear orthologs of their human counterparts
but mice possess two additional loci: Ifitm6, also located on
chromosome 7, and Ifitm7, a retrogene on chromosome 16 [13].
The proteins expressed by these genes restrict influenza A virus
(IAV), filovirus, flavivirus, and SARS coronavirus entry in vitro with
varying efficiencies [4,6]. Ifitm5 expression is limited to bone
[14,15], and the roles of Ifitm6 and 7 are not yet clear. Two strains
of knockout mice were used in the following experiments. IfitmDel
mice lack Ifitm1, 2, 3, 5, and 6 and Ifitm3egfp mice lack Ifitm3 alone
[13].
The aim of the present study was to determine the in vivo
contribution of the Ifitm proteins to the innate immune control of
IAV. We show that Ifitm3 alone makes a significant contribution
to the control of influenza in mice and provide further insight into
its expression and regulation.
Results/Discussion
Murine Ifitm proteins are protective against influenza in
vivo
To determine the in vivo relevance of Ifitm proteins, we
challenged cohorts of IfitmDel, wild type, and heterozygous male
mice with intranasal doses of either 500 or 1000 PFU of influenza
A/PR/8/34 (H1N1) (PR8). In accordance with institutional
policies, mice were considered moribund and euthanized upon
loss of 20% of initial body weight, defined as the 2-day average of
their pre-inoculation weights. At both challenge doses, knockout
mice exhibited significantly accelerated disease progression and
mortality compared to wild type controls (Figure 1A). Heterozy-
gotes had an intermediate phenotype. A modest but insignificant
difference was observed in the mean survival time of knockout
mice receiving each challenge dose, with mice receiving 1000 PFU
surviving 0.7 days longer. With the 500 PFU challenge dose, two
of five wild type animals survived acute infection but disease
remained uniformly lethal in knockout mice. Weight loss at days 3
and 5 was significantly increased in IfitmDel and heterozygous
animals as compared to wild type controls (Figure 1B; plots of
body weight in Figure S1A).
Weight loss in wild type animals receiving a 500 PFU
challenge followed trends reported by other investigators [16].
Price et al. found that mice generally maintained body weight
until day 4–5 post-infection, after which they underwent a rapid
period of weight loss that continued until day 8–9. The rapid
clinical progression beginning on day 4–5 coincided with the
onset of cellular and humoral immunity while recovery on day 8–
9 corresponded to clearance of the virus. In contrast to wild type
animals, IfitmDel mice began a steep decline in weight beginning
on day 2 consistent with a failure of innate control of early
infection. The variability in the rate of disease progression of
knockout mice was also far lower than that of both wild type and
heterozygous animals (Figure S1A). These results demonstrate
that Ifitm proteins mediate innate immunity to influenza A virus
during acute infection and that the effect of their deletion is
powerful enough to overwhelm other sources of experimental
variation. The intermediate phenotype of heterozygous animals
shows that gene dosage is important for Ifitm protein-mediated
viral restriction. The requirement for high gene dosage may also
explain the duplication of the Ifitm alleles observed in multiple
species.
Viral loads are higher in infected IfitmDel knockout mice
Viral loads were measured in a separate cohort of mice
euthanized three days after infection, the period during which
body weights of wild type and IfitmDel animals diverge (Figure
S1A). Weight loss trends in this cohort of animals were similar to
those of previous cohorts (Figure S1B). Viral loads, as assessed by
real-time RT-PCR of lung RNA, were 2.7-fold higher on average
(p=0.0159) in IfitmDel mice as compared to wild type controls
(Figure 1C). Differences in splenic viral loads (Figure 1C) were
similarly increased (15.9-fold, p=0.0079).
Although the relative difference in splenic viral loads was high,
IAV genome copy numbers in the spleen were on the order of 10
4
to 10
5 times lower than those in the lung (Figure S1C) and genome
expression in the spleens of wild type animals was barely above the
detection threshold of our assay. Similarly, we did not identify
splenic lesions or any other lesions beyond those in the lungs,
trachea, and nasal passages, consistent with the dependence of
PR8 hemagglutinin on respiratory proteases for cleavage and
activation [17,18,19,20]. We therefore speculate that increased
splenic viral loads in knockout mice are a result of more robust
infection in the lung and subsequent leakage of virus or viral debris
into the periphery.
Ifitm3-specific and IfitmDel knockout mice are equally
susceptible to IAV infection
Previously, we reported that murine embryonic fibroblasts
(MEFs) derived from IfitmDel knockout mice are highly suscep-
tible to IAV and that both baseline and interferon-induced Ifitm
protein expression contribute to the IAV resistance in wild type
MEFs [2]. Ifitm3 expression alone was sufficient to restore IAV
entry restriction to knockout fibroblasts [9]. We have shown that
over-expression of most murine Ifitm proteins in a human cell
line confers some level of IAV restriction but that Ifitm3 is most
effective while Ifitm5, 6, and 7 posses comparatively little activity
[4]. We confirmed this observation in the context of IfitmDel
MEFs (Figure S2A); again murine Ifitm3 demonstrated the most
potent IAV restriction activity regardless of HA type, likely in
part due to its higher steady-state expression level (Figures S2B
and S2C).
Although Ifitm3 most effectively restricts IAV in vitro, most
human and murine Ifitm proteins restrict IAV to some extent
when over-expressed [4]. To determine the specific in vivo
contribution of Ifitm3, we performed an additional intranasal
challenge of wild type, IfitmDel, and Ifitm3-specific (Ifitm3egfp)
knockout mice with 500 PFU of PR8. Mortality and weight loss
trends of IfitmDel and wild type animals were similar to those of
Figure 1 above. Survival times of Ifitm3-specific knockout mice
were not significantly different from those of IfitmDel knockout
Author Summary
The human genome contains many genes devoted to
combating viral infections. Some of these genes encode a
family of proteins called interferon-induced transmem-
brane (IFITM) proteins which were recently discovered to
inhibit infection by influenza A viruses in cell culture
experiments. Here we show that genetically engineered
mice lacking the murine equivalents of the human IFITM
genes are more susceptible to influenza than mice with a
full complement of these genes. In addition, deletion of
one of these genes alone, Ifitm3, made mice equally
susceptible to infection, showing that the Ifitm3 protein
plays a central role in the control of influenza A virus in
living animals. We also show that murine Ifitm proteins are
expressed on cells targeted by influenza A viruses and that
the control of their expression in animals is more complex
than suggested by previous cell culture studies.
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PLOS Pathogens | www.plospathogens.org 2 September 2012 | Volume 8 | Issue 9 | e1002909Figure 1. An Ifitm locus deletion renders mice more susceptible to influenza. IfitmDel knockout mice challenged intranasally with either
1000 or 500 PFU of influenza A/PR/8/34 (H1N1) (PR8) exhibited more rapid disease progression and higher mortality than wild type and heterozygous
controls. (A) At 1000 PFU, a survival analysis between wild type and knockout animals showed significant differences (p=0.0067, Mantel-Cox test) in
survival time as did a comparison of wild type and heterozygous mice (p=0.0266). With a 500 PFU challenge, survival differences between all pairs of
groups were statistically significant: wild type and knockout (p=0.0011), wild type and heterozygous (p=0.0366), heterozygous and knockout
(p=0.0012). At both challenge doses, heterozygous animals exhibited an intermediate phenotype consistent with a gene dosage requirement for the
antiviral effects of Ifitm.( B) Weight loss measurements from all surviving study animals at 3 and 5 DPI are shown. Closed symbols represent animals
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genotypes were superimposed (Figures 2A and B). As with the
IfitmDel mice, heterozygotes of the Ifitm3-specific knockout mice
exhibited an intermediate phenotype. We therefore conclude that,
among Ifitm proteins, only Ifitm3 makes a substantial contribution
to PR8 resistance in vivo.
challenged with 1000 PFU and open symbols represent animals challenged with 500 PFU. At both time points, weight loss differences between any
two genotypes were statistically significant (Mann Whitney U test). Bars show mean 6 SEM. (C) Pulmonary and systemic viral loads were measured at
3 DPI from animals challenged with 500 PFU of PR8. The relative abundance of IAV M2 transcript levels from total lung or spleen RNA, normalized to
endogenous Gapdh transcript, is shown. Values represent fold changes relative to the mean viral burden of wild type mice. Pulmonary viral loads
were 2.7-fold higher in knockout than in wild type controls (p=0.0159, Mann Whitney U test). Error bars show mean 6 SEM. Splenic viral loads were
15.9-fold greater in knockout than wild type animals (p=0.0079), but splenic viral loads of wild type animals were barely above the detection
threshold of the assay. Splenic viral loads of heterozygotes were not significantly different from those of wild type or knockout animals but a non-
significant trend was evident across all three genotypes.
doi:10.1371/journal.ppat.1002909.g001
Figure 2. IfitmDel and Ifitm3-specific knockout mice exhibit indistinguishable phenotypes. IfitmDel knockout, Ifitm3egfp
2/2 (Ifitm3-specific
knockout), Ifitm3egfp
+/2, and wild type mice were challenged with 500 PFU of intranasal PR8. No differences were observed in disease progression
between IfitmDel and Ifitm3egfp knockouts. Ifitm3egfp heterozygotes exhibit an intermediate phenotype similar to that of IfitmDel heterozygotes in
Figure 1. (A) Survival times of Ifitm3egfp and IfitmDel knockouts were significantly different from those of wild type animals (p=0.0038 and p=0.0067
respectively, Mantel-Cox test) but not significantly different from one another (p=0.5380). (B) Mean+SD weight loss over time is shown for mice in
Figure 2A.
doi:10.1371/journal.ppat.1002909.g002
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Because the Ifitm3 promoter is sensitive to interferon signaling
we reasoned that other Jak/STAT-mediated cytokines might
likewise induce Ifitm3 expression. We tested the ability of a type
III interferon (IFNl2), the acute phase cytokine IL-6, and
oncostatin M (OSM), a cytokine released from activated dendritic
cells that synergizes with type I interferon [21], to upregulate
Ifitm3 expression. The latter two molecules belong to a diverse
family of cytokines that signal through hetero- or multimeric
receptors that activate the Jak/STAT pathway via a common
gp130 subunit [22]. Consistent with previous studies, type I and
type II interferons induced Ifitm3 expression in both NIH 3T3
murine fibroblasts, and the murine macrophage cell line,
RAW264.7. IFNl2 was ineffective, likely due to lack of the
appropriate receptor. In 3T3 cells, however, oncostatin M (OSM)
induced strong Ifitm3 expression and IL-6 was a potent inducer of
Ifitm3 expression and in RAW264.7 cells (Figure 3A). The ability
of these two cytokines to modulate Ifitm3 expression correlated
with the surface expression of their cognate receptors (Figure 3B),
and was not due to increased expression of type I or II interferons
(Figure S3). These data raise the possibility that other gp130-
mediated cytokines such as IL-11, IL-27, and LIF could modulate
basal and inducible Ifitm3 expression in cells bearing appropriate
receptors. Furthermore, they indicate greater specificity and
complexity in the regulation of Ifitm3 expression, and possibly
other interferon-stimulated genes, than previous studies have
implied.
Human IFITM1, 2, and 3 are interferon-stimulated genes [23].
Murine Ifitm3 is shown to be interferon-inducible but the
regulation of the other murine Ifitms, particularly the mouse-
specific family members Ifitm6 and 7, has not been studied.
Therefore, we assayed the responsiveness of the murine Ifitm
promoters to both type I and type II interferons (Figure 3C). We
observed that, of the murine Ifitm genes, Ifitm3 alone has an
interferon-inducible promoter. Figure 3C also suggests that – at
least under these tissue culture conditions – Ifitm promoters may be
constitutively active, perhaps contributing to an intrinsic antiviral
state. We validated the results of this promoter assay by analyzing
cytokine-mediated upregulation of murine Ifitm1, 2, and 3
transcripts by qRT-PCR. Consistent with the promoter studies,
and in contrast to the behavior of their human orthologs, murine
Ifitm1 and 2 were unresponsive to both type I and type II
interferons. Ifitm3 transcript levels were significantly upregulated
by both IFNa2 and IFNc in both NIH 3T3 and RAW264.7 cells.
Ifitm3 was similarly induced by OSM in 3T3 cells and IL-6 in
RAW cells consistent with both western blot and promoter data
(Figure 3D). Ifitm1 also appeared to respond to OSM stimulation
although this increase was not statistically significant.
Ifitm3 localization is consistent with its role as an IAV
restriction factor
The data in Figures 2 and 3 show that Ifitm3 is the most potent
IAV restriction factor of the murine Ifitm proteins and that Ifitm3
expression alone is efficiently induced interferons. To determine
where and under what conditions Ifitm3 is expressed in vivo,w e
performed comprehensive immunohistochemical staining of the
lungs of infected and uninfected wild type mice to determine
baseline and influenza-induced patterns of Ifitm3 expression.
Contrary to expectations, constitutive expression of Ifitm3 was
seen in many lung tissues; marked induction was seen only in the
respiratory epithelium of lower airways (Figure 4A, B, C). The
pattern of distribution was similar in the remaining lung tissue in
IAV-infected and uninfected mice. Constitutive expression was
observed in respiratory epithelial cells of the upper airways
(Figure 4D, E, F), the visceral pleura (Figure 4G, H, I), and in
leukocytes (Figure 4J, K, L), suggesting that Ifitm3 may provide
protection against influenza prior to the interferon and acute-
phase responses. No immunostaining of Ifitm3-specific knockout
mice was observed, confirming the specificity of the antibody for
Ifitm3 (Figure S4).
We also localized Ifitm3 expression specifically to influenza A
virus target cells – alveolar type II pneumocytes and ciliated
respiratory epithelial cells [24] – by immunofluorescence and
confocal microscopy. Type II pneumocytes were identified by DC-
LAMP expression, a marker of type II pneumocyte-specific
lysosome-related organelles [25]. Ifitm3 is not only expressed by
DC-LAMP positive cells but also colocalizes with DC-LAMP itself,
consistent with previous in vitro reports of its localization to
endosomal/lysosomal membranes (Figure 5A). In contrast, ciliated
respiratory epithelium shows intense labeling of the apical
cytoplasm or plasma membrane rather than the punctate intracy-
toplasmic distribution typical of lysosomes (demonstrated by
lysosomal marker MAC-3; Figure 5B). Whether Ifitm3 functions
differently in the context of these cells or its apical localization is the
end result of endo/lysosomal exocytosis is unknown.
While this manuscript was under review, Everitt et al. published
data showing that Ifitm3-specific knockout mice are more
susceptible to infection with influenza A virus X31 (H3N2) than
wild type controls [26]. They also identified and characterized a
polymorphism in human IFITM3 associated with reduced
restriction activity and found an increased prevalence of this
mutant allele in patients hospitalized for influenza. Our data
support and extend the core conclusions of their mouse studies.
We further show that mice lacking entire Ifitm locus exhibit a
nearly identical disease course to those lacking Ifitm3 alone, and
that their respective heterozygote littermates exhibit a phenotype
intermediate between knockout and wild type mice. Morever,
Ifitm3 is expressed on key IAV target cells in the lungs, and among
murine Ifitms, is uniquely induced by type I and II interferons.
Collectively these data make clear a primary role for Ifitm3 in the
control of influenza A virus in mice.
We also show that many tissues express basal levels of Ifitm3
proteins, and that at least two gp130-family cytokines – OSM and
IL-6 – can induce its expression, even in the absence of an
interferon response. These results suggest greater complexity in the
in vivo regulation of other well-characterized interferon-stimulated
genes as well. We further noted Ifitm3 expression in cell
populations that are not major IAV targets such as macrophages
and endothelial cells. This implies that Ifitm3 deletion will likely
enhance susceptibility to infections by monocyte-tropic flaviviruses
and macrophage- and endotheliotropic filoviruses.
Our results may also have implications for treatment of viral
infections. The fact that Ifitm3 expression can be induced by
gp130-mediated cytokines may allow for modulation of its
expression in a more targeted, less pleiotropic way by agonizing
or antagonizing cell type-specific gp130 heterodimeric receptors.
More generally, our findings suggest that pharmacologic induction
of human IFITM3 expression or emulation of IFITM3 activity
could provide a broad-spectrum therapeutic approach to the
treatment of a range of human pathogenic viruses.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Ifitm3 Attenuates Influenza In Vivo
PLOS Pathogens | www.plospathogens.org 5 September 2012 | Volume 8 | Issue 9 | e1002909Figure 3. Both interferons and gp130-mediated cytokines induce Ifitm3 expression. Ifitm3 protein expression can also be induced by
gp130-family cytokines in cells expressing appropriate receptors. The Ifitm3 promoter alone among murine Ifitm promoters is interferon responsive.
(A) Expression of Ifitm3 was determined by western blot in NIH 3T3 and RAW 264.7 cells treated for 2 days with the indicated cytokines. IFNl2 failed
to induce Ifitm3 expression at similar concentrations, likely due to lack of the type III IFN receptor. The gp130-family cytokine oncostatin M (OSM) was
a potent inducer of Ifitm3 expression in 3T3 cells whereas RAW264.7 cells were responsive to IL-6, but not OSM. (B) Surface expression of the OSM
receptor, IL-6 receptor, and gp130 by NIH 3T3 and RAW264.7 cells was determined by flow cytometry. Solid blue lines correspond to the fluorescence
Ifitm3 Attenuates Influenza In Vivo
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studies were approved by the Institutional Animal Care and Use
Committee of Harvard Medical School (Protocol Number 04743).
Influenza A virus
Human influenza virus A/PR/8 (H1N1) propagated in chicken
eggs and sucrose gradient purified from allantoic fluid was
obtained from Charles River Laboratories, aliquoted, and frozen.
Titer was determined by standard plaque assay on Madin-Darby
canine kidney cells.
Mice and inoculations
Heterozygous IfitmDel and Ifitm3egfp mice (background strain
C57BL/6J-Tyrc-2J/J) were generously provided by Dr. David
Adams (The Wellcome Trust Sanger Institute, Cambridge, United
Kingdom). These animals were housed under specific pathogen-
free conditions prior to infection. All mice were between 8 and 10
weeks old with the exception of three 12-week-old littermates (one
of each genotype) used in Figure 1A. Mice were anesthetized by
intraperitoneal injection of a cocktail of ketamine (2 mg per 25 g
body weight) and xylazine (0.2 mg per 25 g body weight) in 200 ml
signal of the indicated receptor-binding antibodies and red lines show fluorescence of the isotype control. The responsiveness of 3T3 and RAW cells
to OSM and IL-6 respectively (as shown in panel A) correlates with their expression of their corresponding receptors. (C) Activities of the six murine
Ifitm promoters were assayed in mock-treated, IFNa2-treated, and IFNc-treated NIH 3T3 cells transfected with plasmids encoding luciferase under the
control of the indicated promoters. Ifitm1, 2, and 6 promoters appear constitutively active, and in contrast to human orthologs, insensitive to
interferon stimulation. The Ifitm5 promoter shows almost no activity under any condition, consistent with its tissue-restricted expression in vivo [15].
The Ifitm3 promoter alone is interferon responsive (4.4-fold induction with IFNa2; 2.2-fold with IFNc). Bars show mean of triplicates 6 SEM. Asterisk
indicates p,0.0001 (two-factor ANOVA Bonferroni post test). (D) Cytokine regulation of Ifitm1, 2, and 3 was confirmed at the mRNA level by qRT-PCR
in both 3T3 and RAW cells. Bars depict fold upregulation of the indicated transcripts following a 24-hour incubation with the indicated cytokines
relative to transcript levels in untreated cells. Ifitm3 transcript levels were significantly upregulated by IFNa2 (500 ng/ml) and IFNc (100 ng/ml) in
both cells lines. As in panel (A), OSM (250 ng/ml) upregulated Ifitm3 in 3T3 cells and IL-6 (250 ng/ml) upregulated Ifitm3 in RAW cells. Ifitm1 and
Ifitm2 transcript levels were not increased by interferons. Mean Ifitm1 expression increased in response to OSM treatment but the difference was not
significant due to the high variance of these samples. Error bars show mean 6 range of triplicates. Asterisk indicates p,0.05 and double asterisk
indicates p,0.01 (1-tail t-test assuming heteroscedastic samples).
doi:10.1371/journal.ppat.1002909.g003
Figure 4. Ifitm3 is constitutively expressed by many respiratory tissues and induced in lower airway epithelium by influenza. Many
lung tissues constitutively express Ifitm3. Panels show Ifitm3 expression (stained red/brown) in uninfected wild type (top) and infected wild type
(6 DPI, middle) animals. Comparable tissues from knockout mice (bottom) are included as negative controls. (A–C) Ifitm3 expression was induced on
lower airway (*) epithelium following influenza infection. Constitutive expression was observed on the endothelium of blood vessels (arrowheads).
The endothelial cells in (A) and (B) provide a reference for staining intensity between the two slides. (D–E) In contrast to lower airway epithelial cells,
upper airway epithelial cells constitutively express Ifitm3. Ifitm3 localizes to the apical borders of ciliated epithelial cells (arrows, inset shows
magnified view of indicated cell in which the cilia can be visualized). In the infected animal in (E), the lesioned epithelium has become dysplastic. The
flattened, non-ciliated epithelial cells show punctate cytoplasmic, rather than apical, staining. Interspersed goblet cells (arrowhead) do not stain. (G–I)
Ifitm3 is constitutively and robustly expressed by the visceral pleura. (J–L) Leukocytes (arrows) often strongly express Ifitm3. The arrow in (J) indicates
a circulating leukocyte. In (K), Ifitm3 expression can be seen on inflammatory cells recruited to a pneumonia lesion.
doi:10.1371/journal.ppat.1002909.g004
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with influenza A virus diluted in 50 ml of phosphate-buffered saline
divided evenly between both nostrils and administered over the
course of one to two minutes. Animals were weighed once daily
and, per institutional requirements, euthanized upon loss of 20%
of initial body weight or when deemed moribund based on clinical
signs. All procedures were performed with the approval of
Harvard University’s Institutional Animal Care and Use Com-
mittee.
Viral load measurements
Lungs and spleens were harvested, rapidly frozen, and stored at
280uC prior to RNA isolation. Tissue was thawed in RNALater,
transferred to 1 ml (lungs) or 0.5 ml (spleens) of RNAase-free
water and mechanically homogenized with a QIAGEN TissueR-
uptor. RNA extraction was performed by means of the QIAGEN
RNeasy Tissue Kit and QIAshredder columns (QIAGEN). Viral
loads were determined by real-time TaqMan RT-PCR. Influenza
A viral M2-specific primer and probe sequences were adapted for
use with IAV PR/8/34 from protocols developed by the Centers
for Disease Control [27]. Sequences were: 59-GAC CAA TCC
TGT CAC CTC TGA C-39 (forward primer), 59-AGG GCA
TTT TGG ACA AAG CGT CTA-39 (reverse primer), and 59-
TGC AGT CCT CGC TCA CTG GGC ACG-39 (probe).
Reporter and quencher dyes were FAM and IBFQ respectively
with an additional internal Zen Quencher (Integrated DNA
Technologies). Similarly labeled Gapdh primer and probe
sequences were: 59-GTG GAG TCA TAC TGG AAC ATG
TAG-39 (forward primer), 59-AAT GGT GAA GGT CGG TGT
G-39 (reverse primer), and 59-TGC AAA TGG CAG CCC TGG
TG-39 (probe) (Integrated DNA Technologies). 25 ml reactions
containing 25 ng RNA, 50 pmol each primer, and 25 pmol probe
were prepared using the Superscript III One-Step RT-PCR
System with Platinum Taq DNA Polymerase and ROX (Invitro-
gen). Cycling conditions were: 50uC for 30 min (reverse
transcription), 95uC for 2 min (denaturation), and 45 cycles of
95uC for 15 seconds (dentaturation) and 55uC for 45 sec
(annealing, extension, and fluorescence acquisition). Cycling and
fluorescence detection were performed in an ABI Prism 7500
thermal cycler (Applied Biosystems).
Pseudovirus entry assays
Entry assays were performed on murine embryonic fibroblasts
(MEFs) derived from IfitmDel knockout mice. Cells were
transduced with retroviral puromycin-selectable vectors encoding
the murine Ifitm proteins or with an empty vector control, as
previously described [4]. MEFs were cultured for one week in
puromycin to correct for variation in transduction efficiency. GFP-
encoding retroviruses pseudotyped with PR8 neuraminidase and
IAV HA (derived from influenza A/PR/8/34 (H1N1), influenza
A/Thailand/2(SP-33)/2004 (H5N1), and A/FPV/Rostock
(H7N1)) or the envelope glycoprotein of MLV or LASV were
Figure 5. Ifitm3 is expressed by the target cells of influenza A virus. Ifitm3 is expressed by the target cells of IAV in infected wild type
animals. Laser-scanning confocal micrographs show Ifitm3 (red), influenza A virus antigen (blue), nuclear chromatin (cyan), and either type II
pneumocyte marker DC-LAMP (left, green) or lysosomal marker MAC-3 (right, green), against a differential interference contrast background. Tissues
shown were harvested from an infected wild type animal at 6 DPI. (A) Ifitm3 is expressed on alveolar type II pneumocytes (arrows) marked by DC-
LAMP (green), many of which are Ifitm3 positive (yellow). Occasional infected cells (arrowheads) including an infected Ifitm3 positive cell (magenta)
are scattered throughout the parenchyma. Inset: Ifitm3 colocalizes with the lysosome-related organelle marker of type II pneumocytes, DC-LAMP
(colocalization depicted in yellow). (B) Ifitm3 is localized to the apical membranes of ciliated respiratory epithelial cells (arrows) lining a bronchiole
filled with IAV-infected (blue), necrotic, and Ifitm3-positive cellular debris (*). Ifitm3 does not colocalize with lysosomal marker MAC-3 (green) in these
cells. Inset: magnified view of ciliated cell.
doi:10.1371/journal.ppat.1002909.g005
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were incubated with pseudoviral particles by spin-inoculation at
40006g for 30 minutes at 4uC. Cells were washed and returned to
growth medium. 48 hours later, cells were harvested, fixed in 1%
paraformaldehyde, and GFP expression was quantified by flow
cytometry.
Western blots
RAW264.7 cells and 3T3 cells were incubated with varying
concentrations of IFNa2 (eBioscience), IFNc2 (Antigenix Amer-
ica), IFNc (Antigenix America), IL-6 (Sigma), or OSM (Sigma).
Two days later, cells were lysed with 1% NP40 and lysates were
analyzed by SDS-PAGE and western blot. Goat anti-mouse Ifitm3
antibody (R & D systems) and HRP-conjugated rabbit anti-goat
IgG secondary antibody (Sigma) were used to detect the expression
of Ifitm3. Murine anti-b-tubulin antibody (Sigma) and HRP-
conjugated rabbit anti-mouse IgG secondary antibody (Santa Cruz
Biotechnology) were used to measure the expression of tubulin as a
loading control. Expression of myc-tagged murine Ifitms was
determined using the monoclonal 9E10 antibody (Santa Cruz
Biotechnology).
Flow cytometry
5610
5 NIH 3T3 or RAW 264.7 cells were stained with a panel
of rat monoclonal IgG2a antibodies against the OSM receptor
(clone 30-1, MBL International Corporation), IL-6 receptor (clone
255821, R&D Systems), gp130 (clone 125623, R&D Systems), or
an equal amount of an isotype control antibody (clone eBR2a,
eBiosciences). Secondary labeling was performed with Alexa 488-
conjugated donkey anti-rat (Invitrogen) and fluorescence was
measured on a BD Biosceinces FACSCalibur flow cytometer.
Promoter activity assays
Approximately 800 bp of each murine promoter region was
amplified from wild type MEF genomic DNA and subcloned into
the XhoI and HindIII sites of the luciferase reporter vector pGL3-
Enhancer (Clontech). Primers used were as follows (promoter:
forward/reverse): Ifitm1: 59-CCC CAC ATA AAA GGT CAT
GG-39/59-TCG GCT TTT GAA GCT GCA GA-39, Ifitm2: 59-
CTC CTC CTT GCT CCA TTC TG-39/59-ACT GAC TCT
GGA ACA ATC GC-39, Ifitm3: 59-GAG TGG CTG TAG CAC
CAA CA-39/59-GCG GAG CAA AGG CAG CAC-39, Ifitm5: 59-
CCT CTT TGC CTG CTG TCT TC-39/59-TTC CAG CGC
CGT GTC TTC C-39, Ifitm6: 59-CGA TCC TGT TTT GCC
ATC TT-39/59-TTT GTG CTT AAA GGA AGC AAG GAA-
39, Ifitm7 59-ATT GAG ATG GGG TTT CAC CA-39/59-TTG
GTT TTT GAG GCT GGA AGA G-39. NIH 3T3 cells were
cultured in DMEM supplemented with 10% calf serum (Colorado
Serum Company), non-essential amino acids, and penicillin/
streptomycin. 3T3 cells in 12 well plates were cotransfected with
0.5 mg of the promoter/pGL3 construct and 0.5 mgo fa
glucokinase promoter-driven constitutive b-galactosidase reporter
(pGK-b-gal) as a transfection efficiency control. 3T3 cell
transfection was carried out using the TransIT-3T3 Transfection
Kit (Mirus). Transfection complexes were removed after 6 hours
and growth medium alone or medium containing 100 ng/mL
murine IFNa2 (eBioscience) or IFNc (Antigenix America) was
added to the cells. After 24 hours of stimulation, cells were lysed
and enzymatic activities quantitated by means of the commercial
Luciferase Assay System and b-Galactosidase Enzyme Activity Kit
(Promega) in a Victor
3V plate reader (PerkinElmer). Untransfected
wells were used to determine background signal. Data are
presented as the background subtracted luciferase readout for
each sample normalized to the background-subtracted b-galacto-
sidase readout for that sample.
Ifitm and IFN transcript expression
NIH 3T3 and RAW 264.7 cells were grown in 12-well plates.
Triplicate wells containing subconfluent cells were incubated in
growth medium alone or treated for 24 hours with medium
containing 500 ng/mL IFNa2, 100 ng/mL IFNc2, 250 ng/mL
OSM (3T3 cells), or 250 ng/mL IL-6 (RAW cells). RNA was
isolated from cells by means of the RNeasy Mini Kit and
QIAshredder columns (QIAGEN). 3T3 cells used as controls for
Figure S3 were transfected with 1 5 mg/ml high molecular weight
poly I:C complexed with LyoVec transfection reagent (Invivogen)
for 24 hours before harvest. Primer and probe sequences for
detection of murine Ifitm1, 2, and 3 transcripts follow. Ifitm1: 59-
ACC ACA ATC AAC ATG CCT GA-39 (forward primer), 59-
CAC CAT CTT CCT GTC CCT AGA-39 (reverse primer), and
59-ACA CTC TTC ATG AAC TTC TGC TGC CTG-39
(probe), Ifitm2: 59-TTT TCT CTA CCA CCT CTG TGG T-39
(forward primer), 59-TGA ATC CAC TGT GGA CAG ATA G-
39 (reverse primer), and 59-CGG TCC ACA TCT GCC CCG
CC-39 (probe), and Ifitm3: 59-CTG AAC ATC AGC ACC TTG
GT-39 (forward primer), 59-TTT TGG TGG TTA TCA AGT
GCA CT-39 (reverse primer), and 59-TCC GGT CCT GAA
GTG CTT CAC CCT-39 (probe). Murine IFNb1 was amplified
with: 59-AGA TTC ACT ACC AGT CCC AGA-39 (forward
primer), 59-TGA AGA CCT GTC AGT TGA TGC-39 (reverse
primer), and 59-AGG CAA CCT TTA AGC ATC AGA GGC G-
39 (probe). Murine IFNc1 was amplified with: 59-TCC ACA TCT
ATG CCA CTT GAG-39 (forward primer), 59-CTG AGA CAA
TGA ACG CTA CAC A-39 (reverse primer), and 59-TTC CTC
ATG GCT GTT TCT GGC TGT-39 (probe). Gapdh (see Viral
load measurements above) was used as a housekeeping control.
Primers were 59 labeled with FAM and included 39 IBFQ and
internal Zen quencher dyes (Integrated DNA Technologies).
Cycling conditions were: 50uC for 30 min (reverse transcription),
95uC for 2 min (denaturation), and 45 cycles of 95uC for
15 seconds (dentaturation) and 61.5uC for 40 sec (annealing,
extension, and fluorescence acquisition). All reactions were
performed in duplicate.
Immunohistochemistry, immunofluorescence, and
confocal microscopy
Mouse lungs were inflated with 10% neutral buffered formalin,
fixed for 24 hours, and stored in phosphate-buffered saline prior to
paraffin embedding. 5 mm sections were deparaffinized and
subjected to heat-mediated epitope retrieval in low pH Antigen
Unmasking Solution (Vector Labs). Sections were stained for
Ifitm3 (rabbit, Abcam), influenza A virus H1N1 (goat, Abcam),
Mac-3 (rat IgG2a clone M3/84, BD Pharmingen), and DC-LAMP
(rat IgG2a clone 1010E1.01, Imgenex). Secondary fluorescent
labeling was performed with Alexa Fluor 488, 543, or 633-
conjugated secondary antisera of donkey origin (Invitrogen). Ifitm-
tranduced MEFs grown on 8 well chamber slides were fixed and
permeabilized by immersion in a 1:1 mixture of methanol and
acetone at 220uC for 10 minutes prior to staining. Cells were
stained with primary anti-myc clone 9E11 (Santa Cruz Biotech-
nology) and Alexa Fluor 488-conjugated goat anti-mouse second-
ary antibody (Invitrogen). Slides were coverslipped with ProLong
Gold Antifade mounting medium containing DAPI (Invitrogen).
Imaging was performed on a Leica TCS SP5 laser-scanning
confocal microscope through a 636 1.4 NA oil-immersion
objective.
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with similar slide preparation and primary antibodies. Secondary
labeling and detection were performed with biotinylated horse
anti-rabbit, avidin/biotin/peroxidase complex, and Nova Red
chromagen (Vector Labs). Digital images were color balanced for
publication.
Supporting Information
Figure S1 Weight loss curves for mice in Figure 1.
Weight loss of knockout animals was more rapid and more
uniform than that of heterozygous and wild type controls. (A)
Weight loss over time is shown for individual animals in Figure 1A.
Animals were euthanized at 20% weight loss (dotted line). (B)
Panels show mean+SD of surviving animals from Figure 1A at
each time point. The upward trend in wild type weights at day 8–9
reflects surviving and recovering animals. (C) Weight loss trends of
animals from Figure 1C are plotted as above. Animals were
euthanized on day 3 post-infection (dotted line) in order to
measure viral loads. Heterozygotes in this cohort behaved similarly
to wild type animals as reflected by both weight and viral load
measurements. (D) Pulmonary and splenic viral loads from
Figure 1C are plotted against a common log-scale axis to illustrate
the magnitude of the differences between viral loads in these two
organs. Values are shown relative to the lowest splenic viral load of
the wild type mice.
(EPS)
Figure S2 Ifitm3 expression and anti-IAV restriction
activity are more efficient than other murine Ifitm
proteins. (A) Ifitm-transduced MEFs were challenged with
pseudoviruses bearing various IAV HAs or control envelope
glycoproteins from non-restricted viruses (MLV, LASV). The
graph depicts pseudovirus infection of MEFs transduced to express
the indicated myc-tagged Ifitm protein, normalized to the
infection observed with MEFs transduced with vector alone. The
percentage of infected vector-transduced cells for each pseudovirus
is indicated below. Note that the IAV H1 shown here is derived
from PR8, the virus used for the in vivo challenges in Figure 1. Bars
indicate mean 6 range of duplicates. (B) Expression levels of the
myc-tagged Ifitm proteins in MEFs from panel (A) were
determined by western blot using the anti-myc antibody 9E10.
Ifitm3 is the most abundantly expressed. (C) Ifitm-transduced
MEFs were also examined by confocal microscopy by staining the
N-terminal myc tags (green). Nuclei were stained with DAPI
(blue). Photomultiplier tube gain was adjusted individually for each
panel in order to visualize the more poorly expressed proteins. All
murine Ifitms display similar punctate intracytoplasmic staining.
The non-specific green puncta visible within the nuclei of
untransduced cells may represent staining of endogenous c-myc.
(EPS)
Figure S3 OSM and IL-6 did not detectably upregulate
expression of IFNb1 or IFNc. RNA samples from untreated
and OSM-treated NIH 3T3 cells and untreated and IL-6 treated
RAW cells shown in Figure 3D were assayed for IFNb1 and IFNc
expression by qRT-PCR. Untreated and poly I:C-treated 3T3
cells were included as a positive control for IFN stimulation. (A)
24 hours of OSM stimulation did not upregulate IFNb1 mRNA in
3T3 cells. IL-6 induced a slight but non-significant increase in
IFNb1 transcript levels. Values are normalized to those of
untreated cells. (B) IFNc expression was below the threshold of
detection in both 3T3 and RAW cells regardless of cytokine
treatment. Only poly I:C stimulation resulted in detectable levels
of IFNc transcript, and all values are normalized to this level. Bars
show mean 6 range of triplicates.
(EPS)
Figure S4 The antibody used in Figures 4 and 5 is
specific for Ifitm3. Immunohistochemical staining for Ifitm3
was performed on lung tissue from an Ifitm3 heterozygous mouse
(top panels) and an Ifitm3-specific knockout littermate (bottom
panels) infected with 500 PFU of PR8 and euthanized 3 DPI.
Lack of staining of the Ifitm3-specific knockout mouse confirms the
specificity of the antibody used in Figure 4 for Ifitm3. (A, B) Ifitm3
is localized to the apical cytoplasm or plasma membrane of
bronchiolar epithelial cells as well as luminal inflammatory cells.
(C, D) Lower airway epithelial cells express Ifitm3. (E, F) The
visceral pleura is strongly Ifitm3 positive.
(TIF)
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